Certain deadly diseases in the world don’t have any proper vaccination. One such disease is the mosquito-borne disease, Chikungunya.
Chikungunya is a deadly disease transmitted by mosquitoes. The signs of this fatal disease are a sudden rise of fever coupled with pain in the joints. Besides, one might experience other symptoms like headaches, muscle pain, fatigue, and rash. Once an infected mosquito had bitten a person, the signs of Chikungunya may appear within two to six days after that.
Chikungunya first out broke in Asia, Africa Europe and Islands on the Pacific and the Indian Ocean affecting several regions of the Caribbean Island, United States of America, Latin America, Mexico, and Canada.
Oracle Joins Hands with CNRS and Bristol to Fight Chikungunya
Chikungunya doesn’t have any vaccination. Still, according to a recent study, it has been seen that Oracle with Bristol and CNRS has achieved success to develop a vaccination from this tropical disease using the Oracle Cloud Infrastructure.
The notable team of scientists who were able to develop such a high vaccine used the high-performance cloud infrastructure of Oracle. It helped the team to come up with a tremendous computational approach that resulted in the development of the synthetic vaccine’s accurate digital model.
While the vaccine was developed, the team had to process a vast dataset that was obtained by the microscope. With the help of the Cloud, they were able to do it within a short period and in a cost-effective way.
How Does Oracle Contribute Exactly in This Cause?
Researchers from the French National Centre for Scientific Research and the University of Bristol teamed up with Oracle and Imophoron, a start-up for vaccine innovation to find methods for making thermostable vaccines that can be quickly designed and produced.
As a result of the research, they found a new vaccine type that can be stored even at warmer temperatures, thereby, eliminating the need to refrigerate it. The key findings revealed promising results that can revolutionize the making and deployment of vaccines. To combat Chikungunya, the scientists engineered the vaccine with the help of a synthetic protein shell.
The overall finding required a high level of computation due to large datasets obtained. To this, the high-performing infrastructure of Oracle Cloud-enabled the team to develop a unique computational approach for creating the synthetic vaccine’s precise digital model. Oracle together with the IT specialists from Bristol Matt Williams and Christopher Woods, implemented software packages on the cloud seamlessly.
The founder of start-upImophoron Fred Garzoni said that synthetic biology when combined with cloud computing, it resulted in a win-win situation.
Oracle offers a high level of computation with its proven and efficient Oracle Servers together with processors from AMD, Intel, and Nvidia. Oracle Cloud is capable of accelerating workload even if specialized processors in a great number are required.
Conclusion
The Oracle Cloud Infrastructure is excellent with its amazing functionalities. It is an extraordinary combined effort of Oracle, Bristol, and CNRS to develop a superb vaccine for the deadly disease, Chikungunya.
